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Abstract
Background: Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) bacteremia
is an emerging infection. Our objective was to determine the molecular features of hVISA strains
isolated from bacteremic patients and to compare them to methicillin resistant S. aureus (MRSA)
and methicillin sensitive S. aureus (MSSA) blood isolates.
Results: We assessed phenotypic and genomic changes of hVISA (n = 24), MRSA (n = 16) and
MSSA (n = 17) isolates by PCR to determine staphylococcal chromosomal cassette (SCCmec)
types, Panton-Valentine leukocidin (PVL) and the accessory gene regulator (agr) loci. Biofilm
formation was quantified. Genetic relatedness was assessed by PFGE. PFGE analysis of isolates was
diverse suggesting multiple sources of infection. 50% of hVISA isolates carried SCCmec type I, 21%
type II; 25% type V; in 4% the SCCmec type could not be identified. Among MRSA isolates, 44%
were SCCmec type I, 12.5% type II, 25% type V, 12.5% were non-typable, and 6% were SCCmec
type IVd. Only one hVISA isolate and two MSSA isolates carried the PVL. Biofilm formation and agr
patterns were diverse.
Conclusion: hVISA isolates were diverse in all parameters tested. A considerable number of
hVISA and MRSA strains carried the SCCmec type V cassette, which was not related to community
acquisition.
Background
In recent years there have been growing numbers of
reports from many countries of strains of Staphylococcus
aureus showing heterogeneous intermediate resistance to
vancomycin (hVISA). The frequency of heteroresistance
among MRSA isolates has recently reached 6% to 11% [1-
3]. In our institution there are approximately 200 S. aureus
bacteremias each year. Of these, 50% are MRSA and 6%
demonstrate hVISA resistance [2,3]. Molecular assessment
of the clonal dissemination of hVISA isolates has yielded
conflicting results. Several studies found genetic linkage
between hVISA isolates, reflected by a single pulsed field
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gel electrophoresis (PFGE) clone [4-6], while others
showed that hVISA isolates were genetically diverse [7,8].
The mechanism by which hVISA occurs is still under
investigation. The hVISA phenotype has a thickened cell
wall, altered peptidoglycan cross-linking, altered penicil-
lin-binding protein expression, and slower growth rate [1-
3,7]. Several genes related to cell regulation pathways
have been proposed as involved in the development of
resistance to glycopeptides. For example vraSR,  graSR
saeSR, and agr, [9-12], but the global mechanism of resist-
ance and the interactions between these various pathways
are not clear. Most of hVISA isolates were acquired in hos-
pital settings, and most patients had recurrent hospitaliza-
tions, substantial comorbidities [1-3,7] and poor
response to vancomycin therapy [7,8].
The staphylococcal cassette chromosome (SCCmec)
encodes methicillin resistance as well as genes responsible
for resistance to other antibiotics. At least five different
types of SCCmec were found in S. aureus (SCCmec types I
to V), and SCCmec types IV and V were associated with
community acquired MRSA [13,14]. SCCmec typing has
rarely been performed on hVISA isolates, and when per-
formed, most isolates carried the SCCmec type I and II,
similar to hospital-acquired MRSA [6,14,15].
The accessory gene regulator (agr) operon in S. aureus
coordinates quorum sensing as well as virulence path-
ways. In general, agr  activates genes encoding tissue-
degrading factors (secreted virulence factors) and
represses genes that encode factors important for coloni-
zation (virulence factors expressed on the staphylococcal
cell surface). DNA sequence polymorphisms at this locus
comprise four S. aureus agr groups (I-IV), and S. aureus
strains of specific agr groups have been associated with
certain clinical characteristics. In several studies per-
formed in Japan and the USA, VISA and hVISA clinical iso-
lates belonged to agr groups I or II [16,17].
Similarly, the expression of Panton-Valentine leukocidin
(PVL), a two-component pore-forming cytolytic toxin that
targets mononuclear and polymorphonuclear cells and
causes cell death, has been strongly associated with com-
munity acquired MRSA. However, its association with
hVISA strains has not been defined yet [18].
Many staphylococcal infections are associated with com-
municating cell groups known as biofilms in which cells
are attached to abiotic or biotic surfaces and posses altered
growth rates and altered gene expression profiles com-
pared to planktonic bacteria. It was demonstrated that
hVISA isolates that belonged to agr-group II were defective
in agr-function; conversely, these strains were strong bio-
film producers. These findings led to the hypothesis that
VISA strains may exhibit diminished virulence and might
have an enhanced ability to form a thick biofilm due to
agr-locus inactivation [16].
The purpose of this study was to assess the clonal dynam-
ics of hVISA bacteremia in our hospital, to carry out com-
prehensive phenotypic and genotypic analyses of hVISA,
MRSA and MSSA blood isolates recovered in Israel, and to
determine whether any additional phenotypic or geno-
typic characteristic could be used in the recognition of
hVISA.
Results
The study included 24 hVISA isolates, 16 MRSA isolates
and 17 MSSA isolates. All hVISA isolates were identified as
such by the Etest macromethod and the hVISA phenotype
was confirmed by population analysis in all cases. All
MRSA and MSSA isolates did not demonstrate heterore-
sistance to vancomycin as shown by the etest mac-
romethod.
PFGE of hVISA isolates
The PFGE profiles of hVISA isolates exhibited a large
diversity. Of the 18 isolates examined, 15 different pulso-
types were found, suggesting concomitant multiple
sources of infection (Figure 1). In two cases similar hVISA
pulsotypes between two patients were identified. Simi-
larly, there was a great diversity in the pulsotypes of the
MRSA isolates tested; only one of the MRSA pulsotypes
was similar to one of the hVISA pulsotypes.
SCCmec type
Fifty percent (n = 12), 21% (n = 5) and 25% (n = 6) of the
hVISA isolates carried SCCmec type I, SCCmec type II and
SCCmec type V, respectively. Ten isolates that were non-
typable using Olivera's method carried SCCmec type V by
Zhang's method, except one isolate that was nontypable
by both methods (Figure 2). The distribution of SCCmec
types among the16 MRSA isolates revealed SCCmec type I
in 44% (n = 7), type V in 25% (n = 4), type II in 12.5% (n
= 2) and type IVd in 6% (n = 1). Two isolates were non-
typable using both methods. None of the hVISA or MRSA
isolates with SCCmec type IV or V had antibiotic suscepti-
bility patterns compatible with community acquisition
(Table 1), as almost all isolates were resistant to gen-
tamicin and fluoroquinolones. However, the majority of
these isolates were susceptible to erythromycin and clin-
damycin.
PVL genes
Only one hVISA isolate and two MSSA isolates carried
PVL. Furthermore, even the MRSA isolate with SCCmec
type IVd did not carry the PVL gene.
Agr-genotype
All agr types were represented in the 24 isolates of hVISA
(Figure 3): 37.5% were agr-group I, 50.0% agr-group II,BMC Microbiology 2009, 9:189 http://www.biomedcentral.com/1471-2180/9/189
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PFGE of hVISA, MRSA and MSSA isolates Figure 1
PFGE of hVISA, MRSA and MSSA isolates.
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8.4% agr-group III and 4.1% were non-typable. The 16
isolates of MRSA carried agr-group I (18.8%) and agr-
group II (81.2%). The 17 isolates of MSSA carried agr-
group I (17.6%), agr-group II (41.2%) or agr group III
(29.4%), and 11.8% were non-typable.
Biofilm
Determination of biofilm production Quantitative deter-
mination of biofilm formation showed a strong biofilm
production in 6 of 24 isolates (25%) of hVISA, 9 of 16 iso-
lates of MRSA (55.5%) and 5 of 17 MSSA isolates (29%).
There was no relation between biofilm production and
agr group.
Discussion
Molecular assessment of hVISA isolates indicated a
number of PFGE groups, with no substantive evidence of
clonal dissemination. Isolates that appeared to be clonal
were generally not epidemiologically linked by depart-
ment or by time. Although the molecular epidemiology of
the MRSA isolates in hospitals in Israel has not been
explored yet, the high diversity among MRSA isolates in
our study is remarkable. In previous reports, VISA and
Table 1: Antibiotic susceptibility of hVISA and MRSA isolates which carried SCCmec type IV and V
SCCmec type RIF CLIN ERYT GENT AMIK OFL FUS TMP-SMZ
hVISA
Isolate #
25717 V S R R R S R S S
24406 V S S S R S R S S
18981 V R S S R S R S S
34139 V S S S R S R S S
22035 V S S S R S R S S
7555 V S S S R S R S S
MRSA
Isolate #
13372 V S R R R S R S S
13468 V S R R S S R S S
41901 V S S S R S R S S
41168 V S S S R S R S S
13731 IVd S S S R S R R R
Antibiotic susceptibility of isolates was tested using the disc diffusion method according to the CLSI guidelines.
SCCmec typing among hVISA and MRSA isolates using  Zhang's method [32] Figure 2
SCCmec typing among hVISA and MRSA isolates 
using Zhang's method [32].
agr typing among hVISA, MRSA and MSSA isolates Figure 3
agr typing among hVISA, MRSA and MSSA isolates.BMC Microbiology 2009, 9:189 http://www.biomedcentral.com/1471-2180/9/189
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hVISA strains described in Europe belonged to a restricted
range of epidemic multidrug-resistant MRSA strains [4-8],
a worrisome finding that highlighted the potential of
MRSA strains with reduced susceptibility to vancomycin
to become widespread. However, in our study, genetic lin-
eage was not demonstrated between the hVISA and MRSA
isolates. All hVISA isolates had a similar resistance profile
to multiple antimicrobial agents, including aminoglyco-
sides and fluoroquinolones. This association between
hVISA and a multiresistance phenotype was reported pre-
viously [19].
The majority of hVISA and MRSA isolates in the current
study harbored SCCmec type I or II, consistent with noso-
comial acquisition. However, 25% and 31% of hVISA and
MRSA isolates, respectively, carried the SCCmec types IV
or V that are related to community acquisition [13,14];
none of these patients acquired the infection in a commu-
nity setting, and the antibiotic susceptibility of isolates
was compatible with nosocomial acquisition. Further-
more, the PVL gene was found in only one hVISA isolate.
Our study reasserted that hVISA, as well as nosocomial
acquired MRSA, may carry the so-called community
acquired SCCmec types IV and V. It is possible that these
clones originated in the community and were introduced
by patients who were hospitalized. However, during the
study period there were no truly community-acquired
cases, suggesting that community acquisition is rare.
In that respect, once introduced into the hospital, the
SCCmec type V strains may present a competitive advan-
tage over the predominant endemic multiresistant MRSA
clones, in a similar manner SCCmec type IV now seen in
the United States, where the multiplication and transmis-
sion rates appear superior to those of MRSA strains with
other SCCmec types [20]. Another possibility is that S.
aureus SCCmec type V is originally nosocomial and has
spread to the community. In several other reports, the
SCCmec types common among hVISA isolates were I and
II [6,14,15].
Only 5.2% of the S. aureus isolates in this investigation
contained the PVL gene, supporting the findings of
another study that the prevalence of community MRSA
and carriage of the PVL gene among S. aureus isolates in
Israel is low [21]. The low prevalence of the PVL gene in
our isolates may be due to the impact of geography on the
genetic make-up of S. aureus. Strains of MSSA causing skin
and soft tissue infections in South Africa were significantly
more likely to contain a variety of toxins or leukocidins,
including PVL, than MSSA isolates causing similar infec-
tions from the United States [22]. The current study did
not focus on S. aureus isolated from skin and soft tissue
infections, a clinical condition with which PVL has been
strongly associated, and this might also explain the above
observations.
In several studies on agr  groups among VISA/hVISA
strains, most isolates had agr II polymorphism. It was sug-
gested that loss of function of the agr operon might confer
a survival advantage to S. aureus under vancomycin selec-
tion pressure, particularly in strains with the agr group II
genotype [16,17]. In the present study, agr II was the most
common agr group among MRSA isolates; hVISA isolates
on the other hand, demonstrated high diversity in agr pol-
ymorphism, which supports the suggestion that agr  is
probably not associated with the development of resist-
ance to vancomycin.
Reports regarding biofilm formation and hVISA are con-
flicting. Some demonstrated a reduction of biofilm forma-
tion among hVISA isolates [23], while others documented
an increase [24]. Although hVISA infections are associated
with the presence of foreign bodies [7], we could not find
high incidence of biofilm producers among the hVISA iso-
lates.
Conclusion
hVISA isolates are genetically diverse in their PFGE profile,
their SSCmec and agr types, and most strains in Israel do
not harbor the PVL genes. A considerable number of
hVISA and MRSA isolates in Israel carried SCCmec type V
cassette, which was not related to community acquisition.
Methods
All blood isolates of hVISA that were identified during
2003 to 2006 at the Sheba Medical Center, a tertiary care
center with 1,480 beds, affiliated ambulatory clinics and
long-term care facilities, were included (n = 24). Sixteen
and 17 randomly selected blood isolates of MRSA and
methicillin sensitive S. aureus (MSSA), respectively,
formed the control groups. The study was approved by
Sheba's Institutional Review Board.
Identification and confirmation of methicillin and 
intermediate vancomycin resistance
During 2003-2004, resistance to methicillin was identi-
fied by the Kirbi-Bauer oxacillin disk diffusion method.
Thereafter the method was changed to the cefoxitin disk
diffusion method detailed by the Clinical and Laboratory
Standards Institute [25,26]. All isolates included in the
study were assessed for the presence of hVISA by the Etest
macromethod [27]. Antibiotic susceptibility tests were
performed on fresh samples, because reversion of resist-
ance after laboratory manipulation had been reported
[28]. In brief, strains were grown for 18-24 hours on
blood agar plates. Randomly selected single colonies were
inoculated into fresh brain-heart infusion (BHI) broth.
One hundred microliters of 2.0 McFarland suspensionsBMC Microbiology 2009, 9:189 http://www.biomedcentral.com/1471-2180/9/189
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Table 2: List of primers used for the various PCR reactions
Locus/Type Primer Nucleotide Sequence Size (bp)
SCCmec
A CIF2 F2 TTCGAGTTGCTGATGAAGAAGG 495
CIF2 R2 ATTTACCACAAGGACTACCAGC
B KDP F1 AATCATCTGCCATTGGTGATGC 284
KDP R1 CGAATGAAGTGAAAGAAAGTGG
C MECI P2 ATCAAGACTTGCATTCAGGC 209
MECI P3 GCGGTTTCAATTCACTTGTC
D DCS F2 CATCCTATGATAGCTTGGTC 342
DCS R1 CTAAATCATAGCCATGACCG
E RIF4 F3 GTGATTGTTCGAGATATGTGG 243
RIF4 R9 CGCTTTATCTGTATCTATCGC
F RIF5 F10 TTCTTAAGTACACGCTGAATCG 414
RIF5 R13 GTCACAGTAATTCCATCAATGC
G IS431 P4 CAGGTCTCTTCAGATCTACG 381
pUB110 R1 GAGCCATAAACACCAATAGCC
H IS431 P4 CAGGTCTCTTCAGATCTACG 303
pT181 R1 GAAGAATGGGGAAAGCTTCAC
mecA MECA P4 TCCAGATTACAACTTCACCAGG 162
MECA P7 CCACTTCATATCTTGTAACG
SCCmec type V
Type I Type I-F GCTTTAAAGAGTGTCGTTACAGG 613
Type I-R GTTCTCTCATAGTATGACGTCC
Type II Type II-F CGTTGAAGATGATGAAGCG 398
Type II-R CGAAATCAATGGTTAATGGACC
Type III Type III-F CCATATTGTGTACGATGCG 280
Type III-R CCTTAGTTGTCGTAACAGATCG
Type IVa Type IVa-F GCCTTATTCGAAGAAACCG 776
Type IVa-R CTACTCTTCTGAAAAGCGTCG
Type IVb Type IVb-F TCTGGAATTACTTCAGCTGC 493
Type IVb-R AAACAATATTGCTCTCCCTC
Type IVc Type IVc-F ACAATATTTGTATTATCGGAGAGC 200
Type IVc-R TTGGTATGAGGTATTGCTGG
Type IVd Type IVd-F5 CTCAAAATACGGACCCCAATACA 881
Type IVd-R6 TGCTCCAGTAATTGCTAAAG
Type V Type V-F GAACATTGTTACTTAAATGAGCG 325
Type V-R TGAAAGTTGTACCCTTGACACC
mecA MecA147-F GTG AAG ATA TACCAAGTG ATT 147
MecA147-R ATG CGCTATAGATTG AAAGGAT
Panton-Valentine leukocidin (PVL)
luk-PV-1 ATCATTAGGTAAAATGTCTGGACATGATCCA 433
luk-PV-2 GCATCAASTGTATTGGATAGCAAAAGC
Accessory gene regulator (agr)
agrSa agr1-4Sa-1 ATGCACATGG TGCACATGC
agr-1Sa agr1Sa-2 GTCACAAGTA CTATAAGCTG CGAT 439
agr-2Sa agr2Sa-2 TATTACTAAT TGAAAAGTGC CATAGC 572
agr-3Sa agr3Sa-2 GTAATGTAAT AGCTTGTATA ATAATACCCAG 321
agr-4Sa agr4Sa-2 CGATAATGCC GTAATACCCG 657
Gyrase
gyrA-F AGTACATCGT CGTATACTAT ATGG 280
gyrA-R ATCACGTAAC AGTTCAAGTGTGBMC Microbiology 2009, 9:189 http://www.biomedcentral.com/1471-2180/9/189
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were drawn onto BHI agar plates. Etest strips (AB Biodisk,
Solna, Sweden) for vancomycin and teicoplanin were
applied on the same plate, which was subsequently incu-
bated at 35°C for 48 h. Strains were considered hVISA if
readings were ≥8 μg/ml for vancomycin and teicoplanin
or ≥12 μg/ml for teicoplanin alone. All isolates that were
positive for hVISA using the macromethod were further
tested using population analysis method as previously
described [29]. Briefly, after 24 hours of incubation cul-
tures were diluted in saline to 10-3, 10-6 and 10-8 and
plated on to BHIA plates containing 0.5, 1, 2, and 4 mg/L
vancomycin. Colonies were counted after 48 hours of
incubation at 37°C and the viable count was plotted
against vancomycin concentration. The area under the
curve (AUC) was used to distinguish hVISA from glyco-
peptide susceptible isolates. A ration of the AUC of the test
isolate was divided by the corresponding AUC for a strain
validated against a Mu 3 strain (courtesy of Roland Jones,
JMI Laboratories, North Liberty, IA 52317, USA). The cri-
teria used for detection of hVISA were AUC ≥ 0.9.
Pulsed field gel electrophoresis
Genetic relatedness of hVISA strains digested with SmaI
was assessed by PFGE, as described elsewhere [30]. Strains
were considered indistinguishable if there was no differ-
ence in bands, and related (i.e. variants of the same PFGE
subtype) if they varied by 1 to 3 bands. A PFGE dendog-
ram was constructed using GelCompar II (Applied Maths,
Sint-Martens-Latem, Belgium) to calculate similarity coef-
ficients and to perform unweighted pair group analysis
using arithmetic mean clustering. Dice coefficient with
0.5% optimization and 1.0% position tolerance was used.
Polymerase chain reaction (PCR) for genotyping
Genomic DNA was extracted using Wizard Genomic DNA
Purification Kit (Promega, Madison, WI, USA) according
to the manufacturer's protocol for Gram positive bacteria.
DNA samples were stored at -20°C until used for analysis.
Bacterial determinants that were examined using PCR
assays included PVL, agr groups I to IV, and SCCmec
types. Primers and conditions used to amplify the genes of
interest are described in Table 2. Positive and negative
controls were included in each PCR run.
SCCmec typing
Multiplex PCR was used to determine SCCmec type I-V on
all hVISA and MRSA isolates, according to the methods
published by Oliveira [31] and Zhang [32] using respec-
tively the ReddyMix PCR master mix (ABgene, UK) and
Phusion HF master Mix (Finnzymes, Finland).
Panton-Valentine leukocidin
PVL genes were detected by co-amplification of the lukS-
PV and lukF-PV genes as described by Lina [33], using the
Phusion HF master Mix. S. aureus ATCC 25923 was a pos-
itive control.
Accessory gene regulator
The agr locus was defined by multiplex PCR according to
the published protocol [34].
Assessment of biofilm formation
Biofilm formation was quantified using a colorimetric
microtiter plate assay [35]. Two hundred μL of bacterial
suspension were placed into the wells of sterile 96-well
polystyrene U-bottom microtiter plates. After overnight
incubation, media and non-adherent planktonic bacteria
were removed by gentle washing of the plate with sterile
normal saline. The attached bacteria were fixed by adding
99% methanol to each well, and then the wells were emp-
tied and dried before 200 μL of 2% gentian violet 4% in
12% ethanol was added. The dye bound to the adherent
cells was resolubilized by adding 200 μL of gentian violet
4% in 12% ethanol to each well. The optical density (OD)
of each well was determined photometrically at 595 nm.
Wells originally containing sterile medium and non-bio-
film producing bacteria Staphylococcus epidermidis, ATCC
12228 served as a control. The test was carried out in
quadruplicate. The reference value for calculating adher-
ence was OD 0.126. This number was calculated from the
blank readings as mean + 3 × SD. Readings ≤ 0.126 OD
were classified as a non biofilm producer and readings >
0.126 OD as a biofilm producer [35].
Statistical analysis
Fisher exact test was used for comparing hVISA, MRSA and
MSSA results. Significance level was set at p < 0.05.
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